Amy S. Clark, MD, MSCE

faculty photo
Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Attending, Hospital of the University of Pennsylvania
Physician Lead, Breast Cancer Clinical Research Unit, University of Pennsylvania, Abramson Cancer Center
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-154
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-7096
Fax: 215-615-3349
BS (Biology)
Haverford College, 1999.
MD (Medicine)
Milton S. Hershey Penn State College of Medicine, 2006.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2012.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

I am a medical oncologist who specializes in breast cancer. I only see breast cancer patients in the outpatient setting, but treat patients will all cancers when working in the hospital.

Description of Research Expertise

My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.

Selected Publications

Martei Y M, Chen K, Mamtani R, Shulman L N, Hubbard R A, Clark A: Racial disparities in utilization of first line targeted therapies for metastatic breast cancer. J Clin Oncol 41(16), June 2023.

Ulaner GA, Fowler AM, Clark AS, Linden H: Estrogen Receptor-Targeted and Progesterone Receptor-Targeted PET for Patients with Breast Cancer. PET Clin June 2023.

Lynce F, Stevens L, Li Z, Brock J, Gulvady A, Huang Y, Nakhlis F, Patel A, Force J, Haddad T, Ueno N, Stearns V, Wolff A, Clark A, Bellon J, Richardson E, Balko J, Krop I, Winer E, Lange P, E. Hwang S, King T, Tolaney S, Thompson A, Gupta G, Mittendorf E, Regan M, Overmoyer B, and Polyak K. : A phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer “under review” at Clinical Cancer Research 2023.

Haddad TC, Suman VJ, D’ Assoro AB, Carter JM, Giridhar KV, McMenomy BP, Santo K, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs CJ, Young SO, Clark AS, Ingrid AM, Keyomarsi K, Hobday TJ, Peethambaram PP, O’Sullivan CC, Leon-Ferre RA, Liu MC, Ingle JN, Goetz MP. : Phase II Trial of Alisertib Alone or Combined with Fulvestrant in Endocrine-resistant, Advanced Breast Cancer (TBCRC 041). JAMA Oncology July 2022 Notes: In revision

Marczyk M, Mrukwa A, Yau C, Wolf D, Chen, YY Balassanian R, Nanda R, Parker B A Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, van't Veer L, Symmans WF, Esserman L, Pusztai L : Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 22: S0923-7534, May 2022.

Mankoff D, Clark AS, Edmonds CE, O'Brien SR, Pantel A: 16α-[18F]fluoro-17β-estradiol positron emission tomography (FES-PET) to Measure Regional Estrogen Receptor (ER) Expression in Breast Cancer Journal of Clinical Oncology May 2022.

Martei YM, Clark AS: Navigating Systemic Therapeutic Options for First-Line Metastatic Hormone Receptor-Positive, ERBB2-Negative Breast Cancer Treatment. JAMA Netw Open. 5(4), April 2022.

Parikh RB, Takvorian SU, Vader D, Wileyto EP, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Schulman LN,Mamtani R, Hubbard RA.: Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. J Natl Cancer Inst. 114(4): 571-578, April 2022.

Verbus EA, Rossi AJ, Clark AS, Taunk NK, Nayak A, Hernandez JM, Tchou JC.: Preoperative Use of a Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer. Ann Surg Oncol. 29(3): 1530-1532, March 2022.

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Jelle Wesseling, Martín M, Monte-Millán MD, López-Tarruella S, I-SPY 2 Trial Consortium; Boughey J.C, Goetz M.P, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Mi-Ok K, van 't Veer LG, Esserman LJ, Symmans WF: Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: A multicenter pooled analysis of 5161 patients. Lancet Oncol 23(1): 149-160, Jan 2022.

back to top
Last updated: 07/18/2023
The Trustees of the University of Pennsylvania